Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Friday, 09'th May 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript
10:55am, Thursday, 08'th May 2025
Delcath Systems, Inc. (NASDAQ:DCTH ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard
Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates
09:45am, Thursday, 08'th May 2025
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.43 per share a year ago.
Delcath Systems Reports First Quarter 2025 Results and Business Highlights
07:30am, Thursday, 08'th May 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic live
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U
Delcath Systems to Host First Quarter 2025 Earnings Call
04:01pm, Thursday, 24'th Apr 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it
Delcath Systems (DCTH) Soars 9.8%: Is Further Upside Left in the Stock?
10:05am, Thursday, 10'th Apr 2025
Delcath Systems (DCTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near t
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
05:00pm, Wednesday, 09'th Apr 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the public
Hospitals Experience FOMO In Adopting Delcath's PHP Treatment
11:49am, Wednesday, 02'nd Apr 2025
Delcath Systemsbeat Q4 sales estimates. This was driven by increased adoption of HEPZATO KIT. However, the stock fell due to the Biotech/Medtech bear market. Delcath reported its first profitable quar
Beta Bionics Announces Board Appointment of Gerard Michel
04:45pm, Thursday, 27'th Mar 2025
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment
Wall Street Analysts See a 58.49% Upside in Delcath Systems (DCTH): Can the Stock Really Move This High?
10:55am, Wednesday, 26'th Mar 2025
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 58.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
04:01pm, Monday, 24'th Mar 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
10:46am, Wednesday, 19'th Mar 2025
Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 14'th Mar 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript
02:17pm, Thursday, 06'th Mar 2025
Delcath Systems, Inc. (NASDAQ:DCTH ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gera
